MNPRMonopar Therapeuticsvs its industry peers
A metric-by-metric comparison of Monopar Therapeutics against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MNPRThis | $699M#8 | — | 5.3x#9 | — | — | 12.0%#9 | — | -10.5%#6 | — | — | 83.0%#8 | — |
| GERN | $829M#1 | — | 3.8x#6 | 3497.0x#9 | -60.2%#10 | 52.2%#5 | -28938.8%#10 | -38.2%#10 | -24.8%#5 | — | 2.8%#11 | — |
| CLYM | $817M#2 | — | 3.4x#5 | — | — | 19.0%#8 | — | -25.0%#8 | — | — | 605.7%#1 | — |
| DSGN | $781M#3 | — | 3.9x#7 | — | — | -40.7%#14 | — | -34.6%#9 | — | — | 113.9%#5 | — |
| GYRE | $745M#4 | — | 6.9x#11 | 6.4x#4 | 10.2%#6 | -44.8%#15 | 9.9%#3 | 9.2%#4 | 12.0%#3 | 3#3 | -9.6%#12 | 6.0%#1 |
| ACRS | $737M#5 | — | 5.9x#10 | 94.2x#8 | -58.2%#9 | 50.8%#6 | -975.9%#8 | -52.1%#12 | -65.8%#6 | 3#3 | 173.0%#4 | — |
| COLL | $735M#6 | 17.8x#4 | 2.4x#2 | 0.9x#1 | 23.6%#5 | -8.7%#11 | 23.0%#2 | 20.2%#3 | 62.0%#1 | 4#1 | -36.6%#16 | — |
| NVCT | $711M#7 | — | 78.2x#13 | — | — | -39.2%#13 | — | -291.1%#13 | — | — | 251.8%#2 | — |
| IRWD | $695M#9 | 5.3x#1 | — | 2.3x#2 | -15.7%#8 | 2629.5%#1 | 33.3%#1 | — | 42.6%#2 | — | 224.7%#3 | — |
| ZVRA | $692M#10 | 12.5x#3 | 3.2x#4 | 6.5x#5 | 350.9%#1 | 178.9%#3 | -59.1%#4 | 38.2%#1 | — | — | 60.7%#9 | — |
| NGNE | $678M#11 | — | 3.1x#3 | — | -100.0%#11 | -20.2%#12 | — | -41.6%#11 | — | — | 94.9%#7 | — |
| VSTM | $656M#12 | — | 13.1x#12 | 21.2x#6 | 209.1%#3 | -60.3%#16 | -550.3%#7 | -419.1%#14 | — | — | -20.6%#14 | — |
| CBIO | $647M#13 | — | 4.0x#8 | 59.7x#7 | — | 306.4%#2 | -1407.5%#9 | 0.1%#5 | — | — | 39.4%#10 | — |
| PHAT | $636M#14 | — | — | 3.6x#3 | 216.9%#2 | 33.8%#7 | -91.4%#5 | — | — | 4#1 | -28.4%#15 | — |
| ALT | $633M#15 | — | 1.3x#1 | 15442.8x#10 | 105.0%#4 | 7.3%#10 | -230461.0%#11 | -18.6%#7 | -21.1%#4 | — | -10.6%#13 | — |
| FBIOP | — | 6.7x#2 | — | — | 9.7%#7 | 76.2%#4 | -111.0%#6 | 22.5%#2 | — | — | 110.5%#6 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice